cas 1589082-26-7|| where to buy (S)-2-(piperazin-2-yl)acetonitrile

Nom du produit:(S)-2-(piperazin-2-yl)acetonitrile

IUPAC Name:2-[(2S)-piperazin-2-yl]acetonitrile

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM325414-1g	in stock	ǸǸ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1589082-26-7 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:1589082-26-7; Formule moléculaire:C6H11N3; Point de fusion:-; Code SMILES:N#CC[C@@H]1NCCNC1; Densité:

: Numéro de catalogue:CM325414; Poids moléculaire:125.18; Point d'ébullition:; N° Mdl:; Stockage:

: Piperazines; Piperazine is an organic compound consisting of a six-membered ring containing two nitrogen atoms in opposite positions in the ring. The chemical formula of piperazine is C4H10N2, and it is an important pharmaceutical intermediate. Pyrimidines and piperazines are known to be the backbone of many bulk compounds and important core structures for approved drugs; studies have shown that combining a pyridine ring with a piperazine moiety within a single structural framework enhances biological activity.

: Adagrasib; Jan. 10, 2024, EC approves KRAZATI (adagrasib) as a targeted treatment option for patients with advanced non-small cell lung cancer (NSCLC) with a KRAS G12C mutation.
Adagrasib is an orally available, potent, irreversible, small molecule inhibitor of KRAS G12C mutant isoform for the treatment of solid tumours harbouring KRAS G12C oncogenic driver mutation. Adagrasib covalently binds to the mutant cysteine in KRAS G12C and locks the mutant KRAS protein in its inactive state, thereby preventing downstream signalling without affecting wild-type KRAS protein.